Filing Flows › Regen BioPharma (RGBP) › Q1 FY26
Regen BioPharma (RGBP) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 13, 2026
Regen BioPharma (RGBP) reported revenue of $59K for the first quarter fiscal 2026 (Q1 FY26), 0% from a year earlier and -0.5% from the quarter before. Operating margin was -933.9%.
Regen BioPharma, Q1 FY26: revenue $59K (0% year over year), operating margin -933.9%, net loss $968K, operating cash flow −$198K. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | -0.5% | 0% |
| Operating profit | −$552K | — | — |
| Net earnings | −$968K | — | — |
| Operating cash flow | −$198K | — | — |
What changed
Revenue was $59K in Q1 FY26, roughly flat year over year and down 1% from the previous quarter.
Operating costs exceeded revenue by $552K, an operating margin of -933.9%. Total costs grew 407% against flat revenue. The fastest-growing cost line was General & admin (+1642%). The quarter ended with a net loss of $1.0M, wider than the previous quarter's $572K loss.
Operating cash flow was −$198K. Working capital and other items added $770K.
Questions
What was Regen BioPharma's revenue in the first quarter fiscal 2026?
Regen BioPharma (RGBP) reported revenue of $59K for the first quarter fiscal 2026 (Q1 FY26), 0% from a year earlier and -0.5% from the quarter before.
Was Regen BioPharma profitable in the first quarter fiscal 2026?
Operating loss was $552K (-933.9% of revenue) and net loss $968K.
Source: Regen BioPharma 10-Q on SEC EDGAR.